Experience
I have served as the principal computational lead from inception through launch for two diagnostics products, PCM at Invitae and Guidepoint at Adela. On Adela's next-generation platform, my role expanded further into assay design, wet-lab development, and intellectual property.
What that means
Software architecture is not separate from assay performance, validation, clinical evidence, cost, quality, regulatory pathways, or IP. Building diagnostics taught me to look at the whole system and make the technology serve the product.
I joined ArcherDX when it was an eight-person startup and helped turn research code into production bioinformatics products. Over time I led scientific and engineering teams across fusion detection, somatic variant calling, solid tumor, liquid biopsy, RUO, and IVD products as the company scaled.
I led the computational side of PCM from its beginning through commercial launch, then led a 70-person oncology software organization supporting laboratory-developed tests, research products, companion diagnostics, LIMS, bioinformatics, and validation across US, European, and Japanese pathways.
I helped take Guidepoint, a tissue-free liquid-biopsy MRD product, from inception to launch. I also helped bring a second product to its final commercial assay and algorithm configuration while building the surrounding data, scientific software, LIMS, and AI systems needed to support product development.
For the next-generation platform, I had a substantial role in assay architecture and wet-lab development as well as algorithms, data, and software. I also set patent strategy, worked with counsel, and authored core filings. That experience reinforced how tightly chemistry, computation, product decisions, and intellectual property are connected.
Intellectual property
I have helped shape invention capture and patent strategy, managed outside counsel, and contributed as a named inventor across three public US patent families spanning RNA technologies, ctDNA MRD, and integrated blood-based cancer detection methods.
I do not treat patents as paperwork that happens after engineering. The interesting questions often sit at the boundary between assay design, algorithms, workflows, and product architecture.
Agentic systems can expose new workflows, analyses, and scientific insights. Teams need to think about value creation, provenance, ownership, and invention at the same time they think about automation.